key: cord-0790845-v7af90ts authors: Suaifan, Ghadeer A. R. Y.; Mohammed, Aya A. M.; Alkhawaja, Bayan A. title: Fluoroquinolones’ Biological Activities against Laboratory Microbes and Cancer Cell Lines date: 2022-03-03 journal: Molecules DOI: 10.3390/molecules27051658 sha: 89ee5755a559ecf0b37a9d6a06a975a7c4eb333f doc_id: 790845 cord_uid: v7af90ts Development of novel derivatives to rein in and fight bacteria have never been more demanding, as microbial resistance strains are alarmingly increasing. A multitude of new fluoroquinolones derivatives with an improved spectrum of activity and/or enhanced pharmacokinetics parameters have been widely explored. Reporting novel antimicrobial agents entails comparing their potential activity to their parent drugs; hence, parent fluoroquinolones have been used in research as positive controls. Given that these fluoroquinolones possess variable activities according to their generation, it is necessary to include parent compounds and market available antibiotics of the same class when investigating antimicrobial activity. Herein, we provide a detailed guide on the in vitro biological activity of fluoroquinolones based on experimental results published in the last years. This work permits researchers to compare and analyze potential fluoroquinolones as positive control agents and to evaluate changes occurring in their activities. More importantly, the selection of fluoroquinolones as positive controls by medicinal chemists when investigating novel FQs analogs must be correlated to the laboratory pathogen inquest for reliable results. Antimicrobial prescriptions for the treatment of infections caused in particular by Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa), and Mycobacterium tuberculosis (M. tuberculosis) have been affected by bacterial resistance [1] . Alarmingly, the ever-increasing emergence of resistant strains has globally increased the mortality rates [2] . Several approaches have been followed to develop novel fluoroquinolones (FQs) with enhanced antimicrobial activity and/or to enhanced pharmacokinetic properties to tackle bacterial resistance [3] [4] [5] [6] [7] [8] . With more than 500 newly introduced structural modifications on FQs' key scaffold [9] ; 1-substituted 1,4-dihydro-4-oxo-pyridine-3-carboxylic acid ( Figure 1 ) and the recent approval of delafloxacin in 2017, researchers have focused on embracing the biological activity of FQs, particularly against resistant bacterial strains [10, 11] . Additionally, literature reviews pointed out FQs' potential activities as anticancer, antitumor, antiviral, and antifungal agents in addition to their antibacterial activity where the latter is attributed to their ability to selectively inhibit bacterial type II topoisomerases, DNA gyrase, and/or topoisomerase IV [12] [13] [14] [15] . Currently, FQs are one of the most widely used antimicrobial drugs, with a wide range of indications, covering respiratory infections, urinary tract infections (UTIs), gastrointestinal infections, and gynecologic infections [16] . Moreover, FQs are indicated as a prophylactic treatment in immune-compromised neutropenic patients [17] . FQs are usually classified into four generations with enhanced efficacy and spectrum of activity, along with enhanced safety and pharmacokinetic characteristics ( Figure 2 ) [18, 19] . Ciprofloxacin is the most prosperous derivative, both economically and clinically [20] , and the newer generations such as levofloxacin, gemifloxacin, and moxifloxacin offer enhanced activity against aerobic Gram-negative bacilli and Gram-positive bacteria over ciprofloxacin, e.g., against Streptococcus pneumoniae (S. pneumoniae) and S. aureus [20] . Ciprofloxacin and moxifloxacin retain enhanced in vitro activity against P. aeruginosa [21] . In terms of potency, moxifloxacin is more potent against Gram-positive and anaerobes than ciprofloxacin and levofloxacin. Newer generations displayed potent activity against penicillin-resistant and multidrug-resistant (MDR) pneumococcus and anaerobic bacteria. Recently, delafloxacin was granted approval in 2017 for the systemic treatment of acute bacterial skin infections [22] . Additionally, literature reviews pointed out FQs' potential activities as anticancer, antitumor, antiviral, and antifungal agents in addition to their antibacterial activity where the latter is attributed to their ability to selectively inhibit bacterial type II topoisomerases, DNA gyrase, and/or topoisomerase IV [12] [13] [14] [15] . Currently, FQs are one of the most widely used antimicrobial drugs, with a wide range of indications, covering respiratory infections, urinary tract infections (UTIs), gastrointestinal infections, and gynecologic infections [16] . Moreover, FQs are indicated as a prophylactic treatment in immune-compromised neutropenic patients [17] . FQs are usually classified into four generations with enhanced efficacy and spectrum of activity, along with enhanced safety and pharmacokinetic characteristics ( Figure 2 ) [18, 19] . Ciprofloxacin is the most prosperous derivative, both economically and clinically [20] , and the newer generations such as levofloxacin, gemifloxacin, and moxifloxacin offer enhanced activity against aerobic Gram-negative bacilli and Gram-positive bacteria over ciprofloxacin, e.g., against Streptococcus pneumoniae (S. pneumoniae) and S. aureus [20] . Ciprofloxacin and moxifloxacin retain enhanced in vitro activity against P. aeruginosa [21] . In terms of potency, moxifloxacin is more potent against Gram-positive and anaerobes than ciprofloxacin and levofloxacin. Newer generations displayed potent activity against penicillin-resistant and multidrug-resistant (MDR) pneumococcus and anaerobic bacteria. Recently, delafloxacin was granted approval in 2017 for the systemic treatment of acute bacterial skin infections [22] . •Improved gram-negative coverage compared with first generation FQs •Limited Gram-positive coverage •Coverage of atypical pathogens, enterobacteriaceae, Pseudomonas aeruginosa •Oral and intravenous administration •Similar to second-generation but with modest streptococcal coverage •Enterobacteriaceae, atypical pathogens, streptococci, Pneumoccoci •Oral and intravenous administration •Similar to third-generation, but with improved gram-positive and anaerobic coverages •Enterobacteriaceae, P. aeruginosa, atypical pathogens, MSSA, streptococci, anaerobes, Pneumoccoci •Oral and intravenous administration Widening of the antibacterial activity of fluoroquinolones in relation to their generation. Reproduced/adapted from ref. [13] . Appraisal of the newer FQs' derivatives should be, in part, based on the relevant references. Herein, commonly employed FQ acting as positive controls in antimicrobial bioassays of up-to-date papers were reviewed. These results were reported in a constructive and comparative manner to facilitate the process of developing novel FQs' analogues. The chemical structures and key physical properties of the frequently adopted standard FQs, namely norfloxacin 1, ciprofloxacin 2, levofloxacin 3, and moxifloxacin 4 are summarized in Table 1 . This should provide a facile referral guide to recent research areas concerning FQs derivatives antibacterial inhibitory effect, the adopted testing protocols, and generationsbased comparison between different FQs to be applied in innovative research. Choosing standard FQs will not only affect the assessment of the new counterparts, but also provide a more comprehensive and efficient performance in assays. Table 1 . Most adopted standard fluoroquinolones, their chemical structures, and key physical properties. Structure Generation Physical Properties References Appraisal of the newer FQs' derivatives should be, in part, based on the relevant references. Herein, commonly employed FQ acting as positive controls in antimicrobial bioassays of up-to-date papers were reviewed. These results were reported in a constructive and comparative manner to facilitate the process of developing novel FQs' analogues. The chemical structures and key physical properties of the frequently adopted standard FQs, namely norfloxacin 1, ciprofloxacin 2, levofloxacin 3, and moxifloxacin 4 are summarized in Table 1 . This should provide a facile referral guide to recent research areas concerning FQs derivatives antibacterial inhibitory effect, the adopted testing protocols, and generations-based comparison between different FQs to be applied in innovative research. Choosing standard FQs will not only affect the assessment of the new counterparts, but also provide a more comprehensive and efficient performance in assays. [23, 24] Ciprofloxacin Appraisal of the newer FQs' derivatives should be, in part, based on the relevant references. Herein, commonly employed FQ acting as positive controls in antimicrobial bioassays of up-to-date papers were reviewed. These results were reported in a constructive and comparative manner to facilitate the process of developing novel FQs' analogues. The chemical structures and key physical properties of the frequently adopted standard FQs, namely norfloxacin 1, ciprofloxacin 2, levofloxacin 3, and moxifloxacin 4 are summarized in Table 1 . This should provide a facile referral guide to recent research areas concerning FQs derivatives antibacterial inhibitory effect, the adopted testing protocols, and generations-based comparison between different FQs to be applied in innovative research. Choosing standard FQs will not only affect the assessment of the new counterparts, but also provide a more comprehensive and efficient performance in assays. Appraisal of the newer FQs' derivatives should be, in part, based on the relevant references. Herein, commonly employed FQ acting as positive controls in antimicrobial bioassays of up-to-date papers were reviewed. These results were reported in a constructive and comparative manner to facilitate the process of developing novel FQs' analogues. The chemical structures and key physical properties of the frequently adopted standard FQs, namely norfloxacin 1, ciprofloxacin 2, levofloxacin 3, and moxifloxacin 4 are summarized in Table 1 . This should provide a facile referral guide to recent research areas concerning FQs derivatives antibacterial inhibitory effect, the adopted testing protocols, and generations-based comparison between different FQs to be applied in innovative research. Choosing standard FQs will not only affect the assessment of the new counterparts, but also provide a more comprehensive and efficient performance in assays. Appraisal of the newer FQs' derivatives should be, in part, based on the relevant references. Herein, commonly employed FQ acting as positive controls in antimicrobial bioassays of up-to-date papers were reviewed. These results were reported in a constructive and comparative manner to facilitate the process of developing novel FQs' analogues. The chemical structures and key physical properties of the frequently adopted standard FQs, namely norfloxacin 1, ciprofloxacin 2, levofloxacin 3, and moxifloxacin 4 are summarized in Table 1 . This should provide a facile referral guide to recent research areas concerning FQs derivatives antibacterial inhibitory effect, the adopted testing protocols, and generations-based comparison between different FQs to be applied in innovative research. Choosing standard FQs will not only affect the assessment of the new counterparts, but also provide a more comprehensive and efficient performance in assays. A variety of methods and tactics could be adopted to evaluate the antibacterial activity of potential agents, and to draw constructive conclusions. In this regard, choosing and performing these assays varies according to the antimicrobial agents, availability of equipment, and cost-related reasons. The most known and basic standard methods are disk-diffusion [29] and broth or agar dilution methods [30] . The advantages and disadvantages of these assays are summarized in Table 2 and reviewed elsewhere [31, 32] , being apart from the scope of this article. In brief, standardized antimicrobial bioassays (antimicrobial susceptibility testing) are nowadays published and approved by the Clinical and Laboratory Standards Institute (CLSI) for bacteria and yeasts testing [33] , herein the most commonly reported bioassays and the antimicrobial values of various FQs analogues are reported. Dilution methods afford quantitative evaluation of the in vitro antimicrobial activity, which are usually expressed as minimum inhibitory concentration (MIC) values and represent the lowest concentration of the tested antimicrobial agent that inhibits the visible growth of tested microorganism. A number of approved guidelines for dilution antimicrobial susceptibility testing of fastidious or non-fastidious bacteria, yeast, and filamentous fungi are reported [30] . On the other hand, agar disk-diffusion method is the standard qualitative method for routine antimicrobial susceptibility testing. This method provides qualitative results by categorizing bacteria as susceptible, intermediate, or resistant based on the obtained growth zones of inhibition (ZOI) diameters. However, important parameters, including the growth media, temperature, period of incubation, and the required inoculum size should be optimized to fulfil CLSI standards [22] . Differently, measuring the inhibition of supercoiling activity (catalytic activity) of DNA gyrase or the concentration of compounds required for inhibiting 50% of gyrase supercoiling activity (IC 50 ) has been widely reported as an alternative assay to test the antibacterial activity of different FQs derivatives, particularly if the mechanistic and catalytical activity of the developed analogues are of concern [34, 35] . According to the reviewed literature in the past five years, and for the sake of including up-to-date activities on the most common FQs applied as golden antimicrobial positive controls in laboratories, herein, standard FQs and their antimicrobial activity against a panel of laboratory microbes are reported ( Table 3) . As reported, norfloxacin was used as a positive control in the pipeline publications, including norfloxacin derivatives synthesis. Norfloxacin MIC against Gram-positive is presented in Table 3 [45] in the above-mentioned two different studies. 1.509 [48] 0.082 [67] 1.509 [60, 61] 0.296 [50] 0.680 [51] 0.755 [55] ATCC 25923 0.755 [64] 2.960 [57] 0.010 [52] 0.755 [26] 0.368 [46] 3.954 [28] 3.018 [62] Healthcare-acquired MRSA NRS70 0.604 [50] Community-acquired MRSAUSA300 19.014 [50] (MRSA) ATCC 33591 1.509 [60, 61] 0.755 [55] 0.680 [51] MRSA ATCC 33592 ≤0.083 [56] NCDC 110 150.901 [42] 12.072 [47] 0.589 [49] 0.377 [24] As illustrated in Table 3 , ciprofloxacin was the most commonly adopted reference by the cited researchers against different Gram positive and negative bacterial stains, ciprofloxacin [26] , whereas it showed very limited activity against MSSE14-2 strain (MIC > 386.308 µM) [53, 54] . Interestingly, discrepancy in MIC values was observed between similar bacterial strains as reported by different research groups with 100-fold MIC difference [48, 49] . Minor variation between the adopted testing protocol for MIC determination, such as incubation temperature might be the driving factor for such a difference [48, 49] . Considering the third FQ reference, levofloxacin was adopted by many researchers' as a reference control, and exhibited variable antimicrobial activity against E. faecalis (MIC ranged from 1.384 µM for E. faecalis 51575 [55] , 177.220 µM for E. faecalis ATCC 700221 [51] ) as an example. A notable difference in levofloxacin potency against different staph strains, including methicillin-sensitive S. aureus (MSSA) [26, 53, 54, 68, 69] , methicillinresistant S. aureus (MRSA) [26, 53, 54, 68, 69] , S. epidermidis, and S. pneumoniae was observed (Table 3) . Following scientific reports in the literature, levofloxacin exhibited superior antibacterial activity against Gram-positive S. epidermis strains [51, 55, 63] and moxifloxacin is generally the most potent amongst FQs a, gainst Gram-positive and negative bacteria [26] . Moxifloxacin was the latent agent against the food poisoning pathogen L. monocytogenes ATCC 43251 (MIC < 1.370 µM [28] ) when compared with other FQs as ciprofloxacin (MIC 3.954 µM−12.072 [28, 64] ) and norfloxacin (MIC < 8.267 µM [28] ). A summary of common laboratory tested Gram-negative bacteria and standard fluoroquinolones antibiotics are presented in Table 4 . It is noticeable that ciprofloxacin has potential antibacterial activity against Gram-negative bacteria as P. aeruginosa and E. coli. [28, 48] . Moreover, ciprofloxacin had prospective growth inhibitory activity against H. pylori NCTC 11916 and 12 more H. pylori clinical isolates as reported by Abu-Sini et al. [72] . Ciprofloxacin broad spectrum of activity against aerobic and anaerobic Gram-negative bacteria is shown in Table 4 . Nevertheless, Gorityala et al. [56] reported that ciprofloxacin potency against P. aeruginosa were superior compared to moxifloxacin. This pattern was also noticed in results published by Türe et al. and Garza et al., [28, 50] . Norfloxacin inhibitory activity against a panel of Gram-negative bacterial type, and on the same bacterial strain is noted to be varied. For instance, norfloxacin in vitro antibacterial activity reported by Pardeshi [49] in different publications. This fluctuation in ciprofloxacin antibacterial activities may explain the current abundant application of levofloxacin and moxifloxacin as positive standards by medicinal chemists when designing and synthesizing novel FQs analogues [24, 28, [53] [54] [55] [68] [69] [70] [73] [74] [75] . CAN-ICU 63169 6.036 [21] A. coacetius ATCC 19606 1.509 [55] 1.360 [51] C. freundii ATCC 43864 ≤0.091 [55] 1.380 [51] E. aerogenes ATCC 13048 ≤0.080 [51] ≤0.091 [55] E. cloacae ATCC 43560 ≤0.091 [55] ≤0.080 [51] E. coli [21, 52] ATCC 25922 <1.811 [28, 63] 0.024 [54, 57] 0.031 [48] 0.010 [66] 61.869 [49] 0.091 [62] 0.002 [24] NR 17663 0.002 [24] NR 17666 0.045 [24] NR 17661 96.577 [24] ATCC 25922 ESBLs(-); ≤0.091 [55] ≤0.080 [51] ATCC 25922 (wild type) ≤ 0.091 [76] ATCC 35218 0.045 [60, 61] 16.961 [34] ≤0.080 [51] BW5328/pAH69 (wild type) ≤ 0.091 [76] CAN-ICU 61714 (GEN-R) ≤0.755 [21] CAN-ICU 63074 (AMK 32) ≤0.755 [21] CANWARD JW5503-1 (∆toIC) ≤0.0.091 [76] MC4100 (wild type) ≤0.091 [76] NB27005-CDY0039 (∆tolC, gyrA S83L D83G, parC S80I) 6 .036 [76] ≤0.755 [21] 1.811 [28] 0.755 [62] 0.050 [66] ATCC 35657 0.021 [60, 61] ATCC 700603 ESBLs (+) 1.509 [55] 1.360 [51] 0.755 [63] 7 ESBLs(-) ≤0.091 [55] 7 ESBLs (-) ≤0.080 [51] ESBL + 14-17 1.509 [54] ESBL + 14-18 1.509 [54] ESBL + 14-19 193 .154 [54] 14-1 96.577 [54] 14-2 48.288 [54] 14-3 >386.308 [54] 14-4 96.577 [54] K. pneumonia 40.160 [78] M. catarrhalis ATCC 25238 0.091 [60, 61] M. morganii ATCC 25830 ≤0.091 [55] ≤0.080 [51] P. aeruginosa ATCC 9027 0.720 [57] 1.177 [44] ATCC 15442 0.755 [48] ATCC 43288 <0.091 [62] 3.954 [28] ATCC 27853 1.509 [48] 1.509 [54] 0.680 [51] 0.755 [55] ATCC 49565 ≤0.080 [51] 13-1 ≤0.091 [55] P. rettgeri ATCC 31052 ≤0.091 [55] ≤0.080 [51] P. vulgaris ATCC 29905 ≤0.091 [55] ≤0.080 [51] C. freundii ATCC 43864 ≤.0.083 [55] ≤0.080 [51] E. aerogenes ATCC 13048 0.166 [55] 0.170 [51] E. cloacae ATCC 43560 ≤.0.083 [55] ≤0.080 [51] E. coli ATCC 25922 0.346 [68] 0.0412 [24] <0.022 [69] ATCC 25922 ESBLs − ≤0.083 [55] 88.610 [51] ATCC 35218 ESBLs + ≤0.080 [51] NR 17663 0.083 [24] NR 17666 0.083 [24] NR 17661 88.552 [24] 12-6 0.692 [69] 12-11 11.069 [69] ESBL + 14-1 11.069 [54] 44.276 [69] 5.534 [68] M. morganii ATCC 25830 ≤0.083 [55] ≤0.080 [51] ATCC 49565 ≤0.080 [51] P. rettgeri ATCC 31052 ≤0.080 [51] ≤0.83 [55] P. vulgaris ATCC 29905 ≤0.080 [51] ≤0.083 [55] S As presented in Table 4 , different studies reported the use of third generation levofloxacin as a positive control against a wide range of Gram-negative organisms includes P. aeruginosa. For this infectious pathogen, MIC ranged from 5.453 µM [68] for P. aeruginosa 14-19 strain to 87.241 µM [69] for P. aeruginosa 12-14 strain. Similarly, levofloxacin MIC against K. pneumonia ranged from 0.082 µM [69] for K. pneumonia 12-4 strain to 87.241 µM [54] for K. pneumonia 14-3 strain. According to Zhang et al., [69] levofloxacin is around five hundred time more potent against K. pneumonia 12-4 strain compared to P. aeruginosa 12-14 strain, though both are Gram-negative pathogens. However, in another by Huang et al. [68] , levofloxacin was more potent against P. aeruginosa for 14-19 strain compared to K. pneumonia for 14-2 strain. It is worth mentioning that the bacterial strain is the variant factor in both articles. This indeed highlights the importance of referring to the relevant standard control during laboratory investigation and comparisons. A similar pattern of the wide range of MIC values against the same strain was observed, where the MIC of norfloxacin against E. coli ATCC-25922 ranged from <0.094 µM [24] to 117.433 µM [45] . FQs, particularly ciprofloxacin was included as a positive control along with isoniazid and rifampicin against various Mycobacterium strains as shown in Table 5 [24, [26] [27] [28] 58, 63, 65, 68, 75, 81, 82] . Furthermore, levofloxacin in vitro anti-mycobacterial activity was reported and found to be comparable to ciprofloxacin [26, 68] . Recent studies by Hu et al., [82] and Mohammed et al., [65] declared moxifloxacin in vitro anti-mycobacterial activity to be more potent than both ciprofloxacin 1 and levofloxacin 3. Apart from their antibacterial activity, FQs were also tested for their antifungal activity with little effect on most fungi. Since the late 1980s, studies revealed anti-trypanosomal activity for the quinolones prototype, nalidixic, and oxolonic acid derivatives [14] . Other studies illustrated the antiparasitic activity of norfloxacin against Plasmodium falciparum and the inhibitory effect of other fluoroquinolones against Plasmodium family [14, 83, 84] . Today, quinolone-amides related derivatives were used to design anti-trypanosomal compounds with many of them presenting potential in vivo activity [85] . Anticancer activity of FQs were also evaluated against a range of cancer cell lines, such as A549 Lung adenocarcinoma, HCT-116 colon cancer, MCF-7 breast cancer cell lines, and others have been determined previously and compared with the developed counterparts [48, 50, 61, 66] as presented in Table 6 . Micrococcus luteus (M. luteus); Candida albicans (C. albicans); Saccharomyces cerevisiae (S. cerevisiae); Aspergillus clavatus (A. clavatus); Trypanosoma brucei (T. brucei); lactate dehydrogenase (LDH); The half maximal inhibitory concentration (IC 50 ). Minimum inhibitory concentration (MIC); Concentration causing 50% cell growth inhibition (GI 50 ). As researchers investigate several approaches to combat COVID-19 infection, there is a wide interest in fluoroquinolones. Ciprofloxacin and Moxifloxacin were tested through in silico molecular docking and showed the potential binding capacity to SARS-CoV-2 main protease (M pro ) and low binding energy. Moreover, a recent study evaluated the potency and cellular toxicity of selected FQs (enoxacin, ciprofloxacin, levofloxacin, and moxifloxacin) against SARS-CoV-2 and MERS-COV. This study showed that a high concentration of the tested FQs should be employed to prevent viral replication with enoxacin being the superior (EC50 of 126.4) against SARS-CoV-2 [14, 83, 84] . Other studies evaluated FQs anti-HIV-1 activities. However, FQs standards activity were not presented [65] . Based on recently published research where FQs were used as positive controls against several microorganisms and cancer cells, it is recommended to use the most active FQ in future studies in addition to the parent drugs to compare the benefits and to have an accurate insight when reporting results. The difference perceived in FQs' potency according to different research articles is challenging and could be attributed to several factors, including the different testing protocols implemented by each research group, solvents or broth used in bacterial culturing, incubation time, bacterial concentration tested, bacterial growth phase, reader instrument sensitivity, etc. Ciprofloxacin is recommended to be used as a control against Gram-negative bacteria whether resistant or susceptible. If mainly Gram-positive activity is concerned, levofloxacin or moxifloxacin might be the best choices. The wide-spectrum and potent newer generations should be compared with, when broader comparison is desired. Choose moxifloxacin if the development of newer FQs derivatives is not a biologically-based design. This should provide a proper perspective when reporting novel FQs and their activities. Working against Mycobacterium stains, moxifloxacin was found to be more active compared to the other FQs, thus it is advisable to consider it as a positive control. Moreover, the authors spur adopting preliminary activity testing of the chosen strains before commencing biological evaluation of interest as some of the stains might not be susceptible to the reference drugs. Lastly, given that some stains exhibited varied MIC values against the same drug, we recommend revising the adopted protocols beforehand to get more accurate comparable results of the reference drug, which will be then more reliable to base the conclusions upon. Design, synthesis and docking studies of some novel fluoroquinolone compounds with antibacterial activity Changing History; World Health Organization The quinolones: Past, present, and future Design, synthesis, and biological evaluation of 1, 8-naphthyridine glucosamine conjugates as antimicrobial agents 1,8-naphthyridine Glucosamine Derivatives, Their Use in the Treatment of Microbial Infections, and a Method for Preparation 2020-WO202084648 Glycosylated 3-Substituted Fluoroquinolone Derivatives, Preparation Methods Thereof, and Their Use in the Treatment of Antimicrobial Infections 2020, WO2020/202239 1,8-naphthyridine Glucosamine Derivatives, and Uses Thereof for Treating Microbial Recent updates of fluoroquinolones as antibacterial agents Fluoroquinolones structural and medicinal developments Erratum to "Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now? Delafloxacin: First global approval An Introduction to Medicinal Chemistry Ubiquitous nature of fluoroquinolones: The oscillation between antibacterial and anticancer activities Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: A puzzling paradox or a logical consequence of their mode of action? In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections Quinolones: A comprehensive review Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents The new fluoroquinolones: A critical review. Can A critical review of the fluoroquinolones Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux Place in therapy and review of microbiologic, clinical and pharmacologic properties Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates Targeted Antibacterial Activity Guided by Bacteria-Specific Nitroreductase Catalytic Activation to Produce Ciprofloxacin Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: Synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl] fluoroquinolone derivatives containing an oxime functional moiety Design, synthesis, and antimycobacterial activity of novel ciprofloxacin derivatives Design, synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial disk diffusion susceptibility tests 19th ed. approved standard. CLSI Doc Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization Methods for in vitro evaluating antimicrobial activity: A review Current and emerging methods of antibiotic susceptibility testing SLCI Performance Standards for Antimicrobial Disk Susceptibility Tests Design, synthesis, and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase Susceptibility test methods: Dilution and disk diffusion methods Evaluation of the BIOMIC video reader system for determining interpretive categories of isolates on the basis of disk diffusion susceptibility results Antimicrobial susceptibility testing: Currently used methods and devices and the near future in clinical practice Evaluation of the PREVI ® Isola automated seeder system compared to reference manual inoculation for antibiotic susceptibility testing by the disk diffusion method Antimicrobial testing methods Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates Synthesis and biological evaluation of novel benzothiazole clubbed fluoroquinolone derivatives Design, synthesis, molecular docking, and antibacterial evaluation of some novel flouroquinolone derivatives as potent antibacterial agent Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones In vitro antibacterial activity of 7-substituted-6-fluoroquinolone and 7-substituted-6, 8-difluoroquinolone derivatives Novel azole-functionalited flouroquinolone hybrids: Design, conventional and microwave irradiated synthesis, evaluation as antibacterial and antioxidant agents Design, synthesis, antimicrobial, and DNA gyrase inhibitory properties of fluoroquinolone-dichloroacetic acid hybrids Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates Synthesis and Antibacterial Evaluation of New Pyrimidyl N-Ciprofloxacin Derivatives Synthesis and Evaluation of Thiazolidine Amide and N-Thiazolyl Amide Fluoroquinolone Derivatives Synthesis and antibacterial activity of novel Coordination versatility of phosphine derivatives of fluoroquinolones. New Cu I and Cu II complexes and their interactions with DNA Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo) methylpyrrolidine moiety Synthesis and in vitro antimycobacterial and antibacterial activity of 8-OMe ciprofloxacin-hydrozone/azole hybrids Adjuvants based on hybrid antibiotics overcome resistance in Pseudomonas aeruginosa and enhance fluoroquinolone efficacy Synthesis and in vitro activity of 1, 2, 4-triazoleciprofloxacin hybrids against drug-susceptible and drug-resistant bacteria Syntheses and antibacterial activity of N-acylated ciprofloxacin derivatives based on the trimethyl lock Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity New hydroxamic acid derivatives of fluoroquinolones: Synthesis and evaluation of antibacterial and anticancer properties New azetidine-3-carbonyl-N-methylhydrazino derivatives of fluoroquinolones: Synthesis and evaluation of antibacterial and anticancer properties Piperazine-azole-fluoroquinolone hybrids: Conventional and microwave irradiated synthesis, biological activity screening and molecular docking studies In vitro activities of a new fluoroquinolone derivative highly active against Chlamydia trachomatis Pharmacological characterization of 7-(4-(piperazin-1-yl)) ciprofloxacin derivatives: Antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity Synthesis, molecular docking, antimicrobial evaluation, and DNA cleavage assay of new thiadiazole/oxadiazole ciprofloxacin derivatives Organometallic ciprofloxacin conjugates with dual action: Synthesis, characterization, and antimicrobial and cytotoxicity studies Synthesis and antibacterial evaluation of a novel tricyclic oxaborole-fused fluoroquinolone Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3, 5-difluoropyridin-2-yl) fluoroquinolone derivatives containing an oxime functional moiety Synthesis and antibacterial activity of amino acid and dipeptide prodrugs of IMB-070593, a fluoroquinolone candidate New fluoroquinolone compounds with endo-nortropine derivatives at C-7 position show antibacterial activity against fluoroquinolone-resistant strains of Staphylococcus aureus Antibacterial Evaluation and Docking Study of Novel 2-Hydroxy-3-(nitroimidazolyl)-propyl-derived Quinolone ] quinolone derivatives with novel anti-microbial properties against Metronidazole resistant Helicobacter pylori Synthesis and molecular structure of moxifloxacin drug with metal ions as a model drug against some kinds of bacteria and fungi Anionic fluoroquinolones as antibacterials against biofilm-producing Pseudomonas aeruginosa Synthesis and antimycobacterial evaluation of new (2-oxo-2H-chromen-3-yl) substituted fluoroquinolones Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space Antibacterial derivatives of ciprofloxacin to inhibit growth of necrotizing fasciitis associated penicillin resistant Escherichia coli Antibacterial and Urease Inhibitory activity of New Piperazinyl N-4 Functionalized Ciprofloxacin-oxadiazoles Synthesis and antibacterial activity of catecholate-ciprofloxacin conjugates Synthesis and evaluation of antimicrobial activity of [r4w4k]-levofloxacin and [r4w4k]-levofloxacin-q conjugates Ciprofloxacin-1, 2, 3-triazole-isatin hybrids tethered via amide: Design, synthesis, and in vitro anti-mycobacterial activity evaluation Synthesis and in vitro evaluation of novel substituted isatin-propylene-1H-1, 2, 3-triazole-4-methylene-moxifloxacin hybrids for their anti-mycobacterial activities Fluoroquinolone antibiotics exhibit low antiviral activity against SARS-CoV-2 and MERS-CoV Norfloxacin: A new drug in the treatment of falciparum malaria Quinolone amides as antitrypanosomal lead compounds with in vivo activity Design, synthesis and biological activity evaluation of novel pefloxacin derivatives as potential antibacterial agents Synthesis and biological evaluation of novel quinolone derivatives dual targeting histone deacetylase and tubulin polymerization as antiproliferative agents The authors would like to acknowledge The University of Jordan and The University of Petra. The authors declare no conflict of interest.